logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Use of rituximab to decrease panel-reactive antibodies

delete2005-05-01
delete45
PRE
AI
B
Balfour, IC *
A
Andrew C. Fiore
R
Ralph J. Graff
A
Alan P. Knutsen
DOI：10.1016/j.healun.2004.01.006delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Patients with pre-formed antibodies may be at increased risk of rejection after organ transplantation. In this report, we describe the use of rituximab to decrease the percentage of pre-formed antibodies in a pediatric heart transplant recipient. Copyright (c) 2005 by the International Society for Heart and Lung Transplantation.
Keywords:
MYCOPHENOLATE-MOFETIL
MONOCLONAL-ANTIBODY
REJECTION
TRANSPLANTATION
SUPPRESSION

Journal

Journal of Heart and Lung Transplantation cover
Journal of Heart and Lung Transplantation
IF:
6
Papers:
1.4W
Citations:
1.4W

Organization

No organization information available